CHICAGO, April 7, 2025 /PRNewswire/ — Lenire, the first and only FDA Approved tinnitus treatment device of its kind, is proud to sponsor the 10th Annual LexCare Hearing Foundation Hearoes Tour to raise awareness of, and access to, hearing and tinnitus care options for US Veterans.
The Hearoes Tour is a national movement that brings free hearing health resources, screenings, and guidance directly to veteran communities across America.
Hosting over 200 events annually, The Hearoes Tour removes accessibility barriers to hearing and tinnitus care by simplifying the process, addressing affordability concerns, raising awareness of untreated hearing loss side effects, and increasing access to care. To date, the Hearoes tour has conducted over 33,000 hearing screenings and hosted more than 1,000 free hearing health events.
“Nearly 40% of the veterans we’ve served through the Hearoes Tour have reported experiencing tinnitus and yet, for years, we had no real solution to offer them.” said Jaime Motes, Founder/Director, The LexCare Hearing Foundation.
“It’s personal for me — my daughter has cochlear implants because she was born deaf. She has an answer. Every veteran deserves an answer, too. Now, we finally do. Thanks to our partnership with Lenire we are finally able to connect veterans with a real life-changing tinnitus treatment option after years of advocacy, awareness, and outreach.”
“This partnership is a milestone in our mission to eliminate the barriers to hearing and tinnitus care. Together, we are providing real hope and real solutions for those who have sacrificed so much.”
Tinnitus: The #1 Service-Connected Disability
Tinnitus has been the number one service-connected disability compensated for by the VA since 1955. Veterans received an estimated $6.6 billion in service-connected compensation for tinnitus in 2024.1 63% of all auditory Veteran Compensation Claims were for tinnitus.1
Neuromod, the medical device company behind Lenire, was awarded a FSS 65 II Medical Equipment & Supply Contract, making Lenire a treatment option for 3.2 million Veterans living with tinnitus through the Department of Veterans Affairs.1
Lenire is the first bimodal neuromodulation device for tinnitus to receive a Federal Supply Schedule (FSS) Contract. To date, 50 USVA facilities have been trained to provide treatment with Lenire with more scheduled for training in 2025.
“Sponsoring the 10th Annual Hearoes Tour, and supporting the invaluable services The Lexcare Hearing Foundation provides, advances our commitment to veterans by increasing awareness and accessibility of life-changing hearing and tinnitus care treatment options.” said Eric Timm, Neuromod USA CEO and Neuromod Devices President of Global Commercial Operations.
A New Category for Tinnitus Care
Positive results for thousands of tinnitus patients successfully treated with Lenire at independent USA-based clinics has been collected in a growing body of real-world evidence.
In what will be the first of a series of planned real-world evidence publications, results from Alaska Hearing & Tinnitus Center showed that 91.5% of 220 patients reported clinically significant improvement in their tinnitus. 2
This data is consistent with, and in many instances outperforms, data from Lenire’s large-scale clinical trials.
These results followed the publication of Lenire’s pivotal controlled clinical trial results, which led to De Novo US FDA approval and featured as the cover-story in peer-reviewed journal, Nature Communications.3 This article is in the 99th percentile of more than 250,000 tracked Nature articles.
About Neuromod
Founded in 2010, Neuromod Devices Ltd. is a medical technology company headquartered in Dublin, Ireland. Neuromod specializes in the design, development, and commercialisation of neuromodulation technologies to address the clinical needs of underserved patient populations who live with chronic and debilitating conditions.
The lead application of Neuromod’s technology is in the field of tinnitus, where Neuromod has completed extensive clinical trials to confirm the efficacy of its non-invasive neuromodulation platform in this common disorder. For more information visit www.neuromoddevices.com.
About Tinnitus
Tinnitus, commonly known as ‘ringing in the ears’, is a complex neurological condition that causes a perception of sound when there is no external source. Tinnitus affects an estimated 15% of the global adult population.
About Lenire
Lenire is the first non-invasive bimodal neuromodulation tinnitus treatment device shown to soothe and relieve tinnitus in a large-scale clinical trial. Lenire works by delivering mild electrical pulses to the tongue, through an intra-oral component called the ‘Tonguetip®’, combined with auditory stimulation through headphones. This combination drives changes in the brain to treat tinnitus. To date, Lenire has been used in large-scale clinical trials with over 700 patients.
Lenire has CE-mark certification for the treatment of tinnitus under the supervision of an appropriately qualified healthcare professional in Europe and has received a De Novo grant of approval by the US FDA. Further details about Lenire and Clinical Providers at www.lenire.com.
References
1. https://www.benefits.va.gov/REPORTS/abr/docs/2024-abr.pdf
2. https://doi.org/10.1101/2024.08.22.24312175
Photo – https://healthtechnologynet.com/wp-content/uploads/2025/04/Lenire_Hearoes.jpg
SOURCE Neuromod Devices
GUILDFORD, SURREY / ACCESS Newswire / January 12, 2026 / CelLBxHealth plc (AIM:CLBX), a leader…
Ad hoc announcement pursuant to Art. 53 LR 2025 marks a key execution year in…
Preliminary, directional read of planned 88-investor sample indicates heightened proof thresholds (unit economics, reimbursement, outcomes)…
• Patient 1 of Cohort 1 has now completed the 24-month follow-up timepoint, and at…
LegitScript-certified telehealth platform publishes consumer analysis as searches for GLP-1 weight loss information reach record…
Independent investigation examines castor oil, tea tree oil, and salicylic acid formulation claims in the…